First human trial backs GS diabetes benefits

The first human trial on a patented extract of the Gymnema sylvestre (GS) plant has confirmed results from lab tests that the ingredient can help reduce blood glucose, adding weight to its diabetes benefits.

The small-scale trial found that supplementation with the GS extract OSA for 60 days resulted in increased levels of insulin and C-peptide, together with lower levels of blood glucose.

According to Winconsin-based ingredient supplier Ayurvedic-Life International, which sponsored the study, the latest findings support the potential of its patented ingredient for addressing type 2 diabetes.

Gymnema sylvestre, grown primarily in the Indian sub-continent, has been used India for centuries as a traditional folk remedy to help maintain optimal health.

Ayurvedic-Life said its study also confirms previous findings that its isolate stimulates insulin secretion similar to sulphonylureas and meglitinide analogues that are currently used for the treatment of type 2 diabetes.

Read more...